Hengrui Pharmaceuticals' oral small molecule GLP-1R agonist for the treatment of hypertension in combination with overweight or obesity has been approved for Phase III clinical trials.

On January 28th, Hengrui Medicine announced that its subsidiary Shandong Shengdi Pharmaceutical Co., Ltd. has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, allowing the company to conduct phase III clinical trials of the self-developed innovative oral small molecule GLP-1 receptor agonist HRS-7535 tablets for the treatment of hypertension combined with overweight or obesity indications. HRS-7535 tablets is a new type of oral small molecule GLP-1R agonist, and there is currently no oral small molecule GLP-1R agonist available worldwide.